Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 595,198
  • Shares Outstanding, K 78,110
  • Annual Sales, $ 15,530 K
  • Annual Income, $ -87,680 K
  • 60-Month Beta 2.16
  • Price/Sales 1.42
  • Price/Cash Flow N/A
  • Price/Book 0.33
Trade ALGS with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 203.39%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -2.15
  • Number of Estimates 3
  • High Estimate 0.45
  • Low Estimate -4.40
  • Prior Year -10.25
  • Growth Rate Est. (year over year) +79.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.76 +12.72%
on 10/08/24
16.24 -53.08%
on 09/12/24
-6.18 (-44.78%)
since 09/11/24
3-Month
6.76 +12.72%
on 10/08/24
19.50 -60.92%
on 09/09/24
-5.16 (-40.40%)
since 07/11/24
52-Week
6.76 +12.72%
on 10/08/24
30.00 -74.60%
on 03/04/24
-11.63 (-60.42%)
since 10/11/23

Most Recent Stories

More News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS : 7.62 (+10.60%)
Stocks Set to Open Higher as Investors Await Powell Speech, Debt Ceiling Optimism Lifts Sentiment

June S&P 500 futures (ESM23) are up +0.39%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.32% this morning as market participants awaited an update on plans to raise the U.S. debt ceiling while...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
LNC : 32.43 (+3.15%)
PACW : 7.54 (-2.71%)
FSLR : 211.49 (+3.15%)
CS.P.DX : 35.035 (+0.47%)
NGMS : 29.45 (+0.07%)
MMP : 69.00 (+0.67%)
OKE : 96.61 (+2.03%)
ALGS : 7.62 (+10.60%)
DD : 86.53 (+0.25%)
ALB : 102.02 (-0.91%)
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB)...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 7.62 (+10.60%)
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating Aligos Therapeutics, Inc. (NASDAQ: ALGS) to determine whether certain Aligos officers and directors violated securities laws and breached fiduciary...

ALGS : 7.62 (+10.60%)
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort,...

ALGS : 7.62 (+10.60%)

Business Summary

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 8.78
2nd Resistance Point 8.24
1st Resistance Point 7.93
Last Price 7.62
1st Support Level 7.08
2nd Support Level 6.54
3rd Support Level 6.23

See More

52-Week High 30.00
Fibonacci 61.8% 21.12
Fibonacci 50% 18.38
Fibonacci 38.2% 15.64
Last Price 7.62
52-Week Low 6.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar